TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01350752

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: RDTs & Provider Training on Malaria Diagnosis and Treatment
Description: In Cameroon and Nigeria, malaria RDTs will be made available in health facilities and health care providers will receive training and job aids on malaria diagnosis and treatment. The training course covers the following topics: clinical and parasitological diagnosis of malaria, how to use a rapid diagnostic test, algorithm based on malaria test result, recommended treatment for confirmed malaria cases (including dosage and regimen for artemisinin-based combination therapies), advice for treatment of test-negative patients

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: RDTs & Provider Training on Malaria Diagnosis and Treatment
Description: In Cameroon and Nigeria, malaria RDTs will be made available in health facilities and health care providers will receive training and job aids on malaria diagnosis and treatment. The training course covers the following topics: clinical and parasitological diagnosis of malaria, how to use a rapid diagnostic test, algorithm based on malaria test result, recommended treatment for confirmed malaria cases (including dosage and regimen for artemisinin-based combination therapies), advice for treatment of test-negative patients

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Extended provider training (Cameroon only)
Description: 2-day training course which supplements basic provider training on malaria diagnosis and treatment, which focuses on understanding change in malaria treatment guidelines, professionalism, and communication skills

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: School based malaria education (Nigeria only)
Description: Schools will be invited to undertake activities to raise awareness about malaria RDTs and treatment among children and community members. The intervention includes training teachers on peer health education, malaria awareness activities and providing support to hold a malaria educational event
Study: NCT03783000

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 425809
Description: Treatment T

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 425809 mixed with [C-14]-BI 425809
Description: Treatment R
Study: NCT04149470

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omeprazole 20mg BID
Description: High dose PPI therapy (Omeprazole 20mg twice daily)
Study: NCT01235845

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Biological: DC activated CIK combined with DC
Description: Dendritic cells pulsed With tumor lysate were injected back into the patient intradermally close to a lymph node, DC vaccinations will be given every week for a total of four vaccinations.~DC activated CIK combined with IL-2 were injected intratumorally via an Ommaya reservoir every week for a total of two vaccinations.
Study: NCT02340247

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Water

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ursodeoxycholic Acid

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chenodeoxycholic Acid
Study: NCT03825146

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous Multi-lineage Potential Cells (AMPC)
Description: Multi-lineage potential cells which were induced to de-differentiate from somatic leukocytes from peripheral blood. Cells are autologous with respect to the patient, and are prepared in a suspension and administered via intravenous infusion.~An estimated average of 1 x 10\^8 (0.5 to 5.0 x 10\^8) cells/per suspension(275 to 450mL) will be infused into the patient via intravenous infusion on day 5. Cell counts depend on yield of initial leukocyte harvest on day 0.
Study: NCT03213743

Intervention type: DRUG
Group type: OTHER
Intervention: Dexmedetomidine Injection
Description: Investigators gave the patients loading dose of dexmedetomidine for 10 minutes and maintaining dose of dexmedetomidine for 20 minutes. Investigators took blood samples before and after the administration of dexmedetomidine.
Study: NCT02251704

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Blood sampling
Description: Capillary blood samples collected by finger/heel prick for determination of parasite prevalence at the time of survey.

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Assessment of body temperature
Description: Axillary body temperature of all subjects recorded by a digital thermometer at the time of survey.
Study: NCT01247025

Intervention type: OTHER
Intervention: No intervention
Description: This study will not contain a specific intervention
Study: NCT00825942

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: C-KAD Ophthalmic Solution
Description: 4 drops applied daily for 180 days
Study: NCT00504933

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bilastine
Description: 20 mg (encapsulated) tablets QD/14days
Study: NCT02072499

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: KTP Green Light Prostatectomy

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Green Light

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Open prostatectomy
Study: NCT02806570

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mitral valve repair
Study: NCT04121858

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Brain Safe App
Description: The Brain Safe app includes the medication list, a personalized risk calculator, multimedia educational content, and a conversation starter/doctor's report.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Attention Control App
Description: The attention control app, called Med Safe, includes only the medication list feature.
Study: NCT03769415

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intrinsic Subtyping of Primary Breast Cancer
Description: Primary breast tissue will be sent for Nanostring PAM50 Testing to determine intrinsic subtype
Study: NCT03736720

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluorouracil
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liposomal Irinotecan
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Correlative studies
Study: NCT04030130

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: NDURE
Description: NDURE is a theory-based, multi-level Patient Navigation (PN) intervention consisting of three in-person, clinic-based sessions of manualized PN with multiple intervention components that target system- (care coordination), interpersonal- (social support), and individual- (Health Belief Model; perceived susceptibility, severity, barriers, self-efficacy) level health behavior theoretical constructs to reduce barriers to care, improve cancer care delivery, and improve clinical outcomes (timely, equitable PORT). NDURE will be delivered from surgical consultation to PORT initiation (\~3 months).
Study: NCT03065335

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: N-methyl-D-aspartate (NMDA) glutamate receptor (NMDA-R) antagonist

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: N-methyl-D-aspartate (NMDA) glutamate receptor (NMDA-R) antagonist

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: N-methyl-D-aspartate (NMDA) glutamate receptor (NMDA-R) antagonist

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: N-methyl-D-aspartate (NMDA) glutamate receptor (NMDA-R) antagonist

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo comparator

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo comparator
Study: NCT00504933

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cetirizine
Description: 10 mg (encapsulated) tablets. QD/14 days
Study: NCT03065335

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cobot TS MV robotic arm for TMS
Description: TMS-Cobot TS MV \[Axilum Robotics\] robotic arm for spatial positioning and orientation of the TMS coil

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cobot TS MV robotic arm for TMS
Description: TMS-Cobot TS MV \[Axilum Robotics\] robotic arm for spatial positioning and orientation of the TMS coil

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cobot TS MV robotic arm for TMS
Description: TMS-Cobot TS MV \[Axilum Robotics\] robotic arm for spatial positioning and orientation of the TMS coil
Study: NCT02428998

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Korean Red Ginseng

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT00853242

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT03065335

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Cobot TS MV robotic arm for TMS
Description: TMS-Cobot TS MV \[Axilum Robotics\] robotic arm for spatial positioning and orientation of the TMS coil

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Cobot TS MV robotic arm for TMS
Description: TMS-Cobot TS MV \[Axilum Robotics\] robotic arm for spatial positioning and orientation of the TMS coil

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NeurOptics PLRTM-30000 Pupillometer
Description: The Neu-rOptics PLRTM-3000 Pupillometer will use quantitative infrared technology to objectively and accurately measure pupil size and dynamics.
Study: NCT00504933

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: (encapsulated) Tablets QD/14 days
Study: NCT00938639

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CSL425
Description: CSL's 2009 H1N1 Influenza Vaccine, thimerosal 0.01% (weight/volume)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CSL425
Description: CSL's 2009 H1N1 Influenza Vaccine, thimerosal 0.01% (weight/volume)
Study: NCT04876274

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: TMU-LOVE
Description: Patients in intervention group could attend diabetes-related health educational video through the TMU-LOVE platform. Researcher would also send 2-3 videos per week with care massage every 2 weeks to the patients.
Study: NCT02051608

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants received Placebo SC injection Q4W.
Study: NCT04318366

Intervention type: OTHER
Intervention: Observational Study
Description: Not required
Study: NCT00853242

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Genz-644470
Study: NCT02051608

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants received Placebo SC injection Q4W.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gantenerumab
Description: Participants received Gantenerumab at 105 mg , 225 mg, or at doses up to 1200 mg SC injection Q4W.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gantenerumab
Description: Participants received Gantenerumab at 105 mg , 225 mg, or at doses up to 1200 mg SC injection Q4W.
Study: NCT01573572

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pegaptanib sodium injection
Description: 0.3mg of Macugen in a single-use, prefilled glass syringe given every 6 weeks for 48 weeks
Study: NCT06801873

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Endotoxin (E. coli O:113, Reference Endotoxin)
Description: Intravenous administration of 2 ng/kg endotoxin. This is a non-investigational product. Endotoxin is used as challenge agent to achieve a controlled inflammatory state.
Study: NCT00853242

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Genz-644470

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sevelamer carbonate

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sevelamer carbonate

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sevelamer carbonate
Study: NCT00867802

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness-Based Stress Reduction program
Description: Mindfulness- Based Stress Reduction comprising of 8 classes and a one-day retreat, taught over a period of 6 weeks. Intervention also includes practice at home for 20-30 minutes.
Study: NCT01683747

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tranexamic Acid

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Control Intervention (Carrier fluid only)
Study: NCT01164891

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO5185426
Description: Continuous oral dosing b.i.d. , on Day 15 a C isotope labeled dose will be administered
Study: NCT03883919

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-FU
Description: -Standard of care drug

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-FU
Description: -Standard of care drug

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin
Description: -Standard of care drug

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin
Description: -Standard of care drug

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liposomal Irinotecan
Description: -Standard of care drug

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liposomal Irinotecan
Description: -Standard of care drug

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paricalcitol
Description: -Investigational drug

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paricalcitol
Description: -Investigational drug

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Serum and plasma blood samples
Description: -baseline, day 1 of each cycle beginning with cycle 2

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Serum and plasma blood samples
Description: -baseline, day 1 of each cycle beginning with cycle 2

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Tumor biopsy
Description: * 5 patients in each arm will be required to undergo a mandatory tumor biopsy from the primary pancreatic site or metastatic site, if safe and feasible, prior to cycle 1~* After Cycle 3 of treatment, all patients who had a baseline biopsy will be required to undergo a mandatory biopsy of the same site if safe and feasible.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Tumor biopsy
Description: * 5 patients in each arm will be required to undergo a mandatory tumor biopsy from the primary pancreatic site or metastatic site, if safe and feasible, prior to cycle 1~* After Cycle 3 of treatment, all patients who had a baseline biopsy will be required to undergo a mandatory biopsy of the same site if safe and feasible.
Study: NCT00338286

Intervention type: OTHER
Group type: OTHER
Intervention: Standard supportive care (packed RBC transfusion)
Description: Per doctor prescription

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: epoetin alfa + packed RBC transfusion
Description: 40,000 IU SC once a week.
Study: NCT04461691

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Cryoballoon Pulmonary Vein Isolation
Description: Cryoballoon pulmonary vein isolation is a common method for catheter ablation of atrial fibrillation. Cryoenergy is applied through a balloon in a single-step approach resulting in necrosis by tissue freezing.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Cryoballoon Pulmonary Vein Isolation
Description: Cryoballoon pulmonary vein isolation is a common method for catheter ablation of atrial fibrillation. Cryoenergy is applied through a balloon in a single-step approach resulting in necrosis by tissue freezing.
Study: NCT06801782

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Experimental Cognitive training in Immersive Virtual Reality and Telemedicine approach
Description: The cognitive training involved a 4-week immersive virtual reality program to improve planning, cognitive flexibility, and information updating in patients with mild cognitive impairment related to Parkinson's disease. Over 12 sessions of 30 minutes each, participants trained in a virtual supermarket to strengthen attentional and executive skills. The planning task required creating and following a route to collect items while following rules, with increasing complexity. The cognitive flexibility task involved alternating between selecting items from different categories, with difficulty rising due to more categories and distractors. The updating task, set at a virtual checkout, challenged participants to memorize and recall items on a conveyor belt, with difficulty increasing based on sequence length and item count. Progression to higher levels required three successful trials, with feedback provided to support performance improvement

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Active Comparator #1
Description: The active placebo used the same virtual environment, Oculus Go system, and telemedicine setup as the training group, but engaged in tasks with low cognitive demands, mimicking everyday activities. The placebo-planning task involved following a fixed shopping list order in a modified version of the Zoo Map Test. The placebo-shifting task required selecting items from shelves without alternating between categories, while the placebo-updating task involved recalling only the last item from a conveyor belt sequence. The sessions mirrored the training group's structure, with 12 sessions over 4 weeks (3 per week, 30 minutes each), maintaining the same frequency, duration, and levels than Training.
Study: NCT03349801

Intervention type: OTHER
Intervention: No intervention
Description: According to clinical practice.
Study: NCT04579731

Intervention type: DRUG
Intervention: Lactitol Monohydrate
Description: Patients with lower urinary tract dysfunction and assumed to have constipation were placed on lactitol monohydrate 10 g for 8 weeks, and had re-evaluated.
Study: NCT00489541

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Percutaneous Coronary Intervention (PCI) with paclitaxel-eluting stent (TAXUS Element) implantation
Description: TAXUS Element stent implantation
Study: NCT03132207

Intervention type: OTHER
Intervention: Non interventionel study
Description: Only one questionnaire will be done for women and professional
Study: NCT00755144

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: LCS Knee
Description: Cementless total knee arthroplasty with LCS Knee

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ROCC Knee
Description: Cementless total knee arthroplasty with ROCC Knee
Study: NCT01870830

Intervention type: OTHER
Group type: OTHER
Intervention: Altitude exposure
Description: Stay at different altitudes: 490, 1650, 2590 m
Study: NCT03994796

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abemaciclib
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PI3K Inhibitor paxalisib
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Entrectinib
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adagrasib
Description: Given PO
Study: NCT01870830

Intervention type: OTHER
Group type: OTHER
Intervention: Altitude exposure
Description: Stay at different altitudes: 490, 1650, 2590 m

Intervention type: OTHER
Group type: OTHER
Intervention: Altitude exposure
Description: Stay at different altitudes: 490, 1650, 2590 m

Intervention type: OTHER
Group type: OTHER
Intervention: Altitude exposure
Description: Stay at different altitudes: 490, 1650, 2590 m
Study: NCT03582566

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Phonological Awareness
Description: Earobics training

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Working Memory
Description: Cogmed training

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Phonological Awareness + Working Memory
Description: Earobics + Cogmed training

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Active Control
Description: Spashmath
Study: NCT01645046

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Coenzyme A
Description: Coenzyme A 200mg per day.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Coenzyme A
Description: Coenzyme A 400mg per day.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Capsule without coenzyme A.
Study: NCT02339259

Intervention type: OTHER
Intervention: Observation

Intervention type: OTHER
Intervention: Observation
Study: NCT03486509

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Afatinib
Description: afatinb 40mg po bid
Study: NCT03126604

Intervention type: DIAGNOSTIC_TEST
Intervention: female sexual function index
Description: evaluation of sexual functions questionnaire about Desire, Arousal, Orgasm,pain , lubrications, satisfactions

Intervention type: DIAGNOSTIC_TEST
Intervention: female sexual function index
Description: evaluation of sexual functions questionnaire about Desire, Arousal, Orgasm,pain , lubrications, satisfactions
Study: NCT02894099

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Prolonged sitting time
Description: Volunteers will be continuously sitting on a chair for 5 hours and should move the least possible. If the participant needs to stand from the chair, the stage will be invalidated.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PST+Light intensity Short bouts PA
Description: Volunteers will have their time sitting interrupted every 20 minutes for 2 minutes of physical activity of low intensity. In the active period, participants will be encouraged to walk in the hallway and reach a training heart rate between 50-60% HR max predicted for the age and measured by heart rate monitor. The Borg scale will be used at the beginning and the end of each active period in order to measure the subjective effort of the participants. In the end the volunteers will be sitting 5 hours and have 30 minutes (15 bouts of 2 minutes) of light intensity physical activity.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PST+Moderate intensity Short bouts PA
Description: Volunteers will have their time sitting interrupted every 20 minutes for 2 minutes of physical activity of moderate intensity. In the active period, participants will be encouraged to walk in the hallway and reach a training heart rate between 65 a 75% HR max predicted for the age and measured by heart rate monitor. The Borg scale will be used at the beginning and the end of each active period in order to measure the subjective effort of the participants. In the end the volunteers will be sitting 5 hours and have 30 minutes (15 bouts of 2 minutes)of moderate intensity physical activity.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PST+Moderate intensity Long bouts PA
Description: Volunteers will have their time sitting interrupted every 75 minutes for 10 minutes of physical activity of moderate intensity. In the active period, participants will be encouraged to walk in the hallway and reach a training heart rate between 65 a 75% HR max predicted for the age and measured by heart rate monitor. The Borg scale will be used at the beginning and the end of each active period in order to measure the subjective effort of the participants. In the end the volunteers will be sitting 5 hours and have 30 minutes (3 bouts of 10 minutes) of moderate intensity physical activity.